AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. RAPT
  4. [Form 4] RAPT Therapeutics, Inc. Insider Trading Activity

[Form 4] RAPT Therapeutics, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

RAPT Therapeutics director Scott Braunstein received a stock option grant on June 21, 2025, as reported in this Form 4 filing. The derivative securities transaction details include:

  • Grant of 25,000 stock options to purchase common stock
  • Exercise price set at $7.43 per share
  • Options expire on June 21, 2035
  • Vesting schedule: Equal annual installments over three years from grant date

This equity compensation grant appears to be part of the company's standard director compensation program. The options were granted with direct ownership form, and the filing was submitted by attorney-in-fact Rodney Young on June 24, 2025. This transaction represents a new position for the director, as no prior holdings were reported in the filing.

Scott Braunstein, direttore di RAPT Therapeutics, ha ricevuto una concessione di opzioni su azioni il 21 giugno 2025, come riportato in questo modulo 4. I dettagli della transazione di titoli derivati includono:

  • Concessione di 25.000 opzioni su azioni per l'acquisto di azioni ordinarie
  • Prezzo di esercizio fissato a 7,43 $ per azione
  • Le opzioni scadono il 21 giugno 2035
  • Programma di maturazione: rate annuali uguali per tre anni dalla data di concessione

Questa concessione di compensi azionari sembra far parte del programma standard di compensazione per i direttori della societ脿. Le opzioni sono state concesse con forma di propriet脿 diretta e la documentazione 猫 stata presentata dall鈥檃vvocato incaricato Rodney Young il 24 giugno 2025. Questa transazione rappresenta una nuova posizione per il direttore, in quanto non erano state segnalate partecipazioni precedenti nel modulo.

Scott Braunstein, director de RAPT Therapeutics, recibi贸 una concesi贸n de opciones sobre acciones el 21 de junio de 2025, seg煤n se informa en este formulario 4. Los detalles de la transacci贸n de valores derivados incluyen:

  • Concesi贸n de 25,000 opciones sobre acciones para comprar acciones comunes
  • Precio de ejercicio establecido en $7.43 por acci贸n
  • Las opciones expiran el 21 de junio de 2035
  • Calendario de adquisici贸n: cuotas anuales iguales durante tres a帽os desde la fecha de concesi贸n

Esta concesi贸n de compensaci贸n en acciones parece formar parte del programa est谩ndar de compensaci贸n para directores de la empresa. Las opciones se otorgaron con propiedad directa, y la presentaci贸n fue realizada por el apoderado Rodney Young el 24 de junio de 2025. Esta transacci贸n representa una nueva posici贸n para el director, ya que no se reportaron participaciones previas en la presentaci贸n.

RAPT Therapeutics鞚� 鞚挫偓 Scott Braunstein電� 2025雲� 6鞗� 21鞚检棎 欤检嫕 毵れ垬靹犿儩甓岇潉 攵赌鞐皼鞎橃溂氅�, 鞚措姅 鞚� Form 4 鞝滌稖靹滌棎 氤搓碃霅橃棃鞀惦媹雼�. 韺岇儩 歃濌秾 瓯半灅 靹鸽秬靷暛鞚� 雼れ潓瓿� 臧欖姷雼堧嫟:

  • 氤错喌欤茧ゼ 毵れ垬頃� 靾� 鞛堧姅 25,000欤� 欤检嫕毵れ垬靹犿儩甓� 攵赌鞐�
  • 頄夓偓臧�瓴╈潃 欤茧嫻 $7.43搿� 靹れ爼
  • 鞓奠厴 毵岆鞚检潃 2035雲� 6鞗� 21鞚�
  • 氩犾姢韺� 鞚检爼: 攵赌鞐澕搿滊秬韯� 3雲勱皠 毵る厔 霃欖澕頃� 牍勳湪搿� 甓岆Μ 旆摑

鞚� 欤检嫕 氤挫儊 攵赌鞐姅 須岇偓鞚� 響滌 鞚挫偓 氤挫儊 頂勲攴鸽灗鞚� 鞚茧秬搿� 氤挫瀰雼堧嫟. 鞓奠厴鞚� 歆侅爲 靻岇湢 順曧儨搿� 攵赌鞐悩鞐堨溂氅�, 鞝滌稖鞚� 2025雲� 6鞗� 24鞚� 雽�毽澑鞚� Rodney Young鞐� 鞚橅暣 鞚措（鞏挫鞀惦媹雼�. 鞚� 瓯半灅電� 鞚挫偓鞐愱矊 靸堧鞖� 歆�攵勳潉 鞚橂頃橂┌, 鞚挫爠鞐� 氤挫湢 雮挫棴鞚� 氤搓碃霅橃 鞎婌晿鞀惦媹雼�.

Scott Braunstein, directeur de RAPT Therapeutics, a re莽u une attribution d'options d'achat d'actions le 21 juin 2025, comme indiqu茅 dans ce formulaire 4. Les d茅tails de la transaction sur titres d茅riv茅s sont les suivants :

  • Attribution de 25 000 options d'achat d'actions pour acqu茅rir des actions ordinaires
  • Prix d'exercice fix茅 脿 7,43 $ par action
  • Les options expirent le 21 juin 2035
  • Calendrier d'acquisition : versements annuels 茅gaux sur trois ans 脿 partir de la date d'attribution

Cette attribution de r茅mun茅ration en actions semble faire partie du programme standard de r茅mun茅ration des administrateurs de l'entreprise. Les options ont 茅t茅 attribu茅es sous forme de propri茅t茅 directe, et le d茅p么t a 茅t茅 effectu茅 par le mandataire Rodney Young le 24 juin 2025. Cette transaction repr茅sente une nouvelle position pour le directeur, aucun titre ant茅rieur n'ayant 茅t茅 d茅clar茅 dans le d茅p么t.

Scott Braunstein, Direktor von RAPT Therapeutics, erhielt am 21. Juni 2025 eine Zuteilung von Aktienoptionen, wie in diesem Formular 4 gemeldet. Die Details der Derivattransaktion umfassen:

  • Zuteilung von 25.000 Aktienoptionen zum Kauf von Stammaktien
  • Aus眉bungspreis festgelegt auf 7,43 $ pro Aktie
  • Optionen laufen am 21. Juni 2035 ab
  • Vesting-Plan: Gleichm盲脽ige j盲hrliche Raten 眉ber drei Jahre ab dem Zuteilungsdatum

Diese Aktienverg眉tung scheint Teil des standardm盲脽igen Verg眉tungsprogramms f眉r Direktoren des Unternehmens zu sein. Die Optionen wurden in Form von Direktbesitz gew盲hrt, und die Einreichung erfolgte durch den Bevollm盲chtigten Rodney Young am 24. Juni 2025. Diese Transaktion stellt eine neue Position f眉r den Direktor dar, da in der Einreichung keine vorherigen Best盲nde gemeldet wurden.

Positive
  • None.
Negative
  • None.

Scott Braunstein, direttore di RAPT Therapeutics, ha ricevuto una concessione di opzioni su azioni il 21 giugno 2025, come riportato in questo modulo 4. I dettagli della transazione di titoli derivati includono:

  • Concessione di 25.000 opzioni su azioni per l'acquisto di azioni ordinarie
  • Prezzo di esercizio fissato a 7,43 $ per azione
  • Le opzioni scadono il 21 giugno 2035
  • Programma di maturazione: rate annuali uguali per tre anni dalla data di concessione

Questa concessione di compensi azionari sembra far parte del programma standard di compensazione per i direttori della societ脿. Le opzioni sono state concesse con forma di propriet脿 diretta e la documentazione 猫 stata presentata dall鈥檃vvocato incaricato Rodney Young il 24 giugno 2025. Questa transazione rappresenta una nuova posizione per il direttore, in quanto non erano state segnalate partecipazioni precedenti nel modulo.

Scott Braunstein, director de RAPT Therapeutics, recibi贸 una concesi贸n de opciones sobre acciones el 21 de junio de 2025, seg煤n se informa en este formulario 4. Los detalles de la transacci贸n de valores derivados incluyen:

  • Concesi贸n de 25,000 opciones sobre acciones para comprar acciones comunes
  • Precio de ejercicio establecido en $7.43 por acci贸n
  • Las opciones expiran el 21 de junio de 2035
  • Calendario de adquisici贸n: cuotas anuales iguales durante tres a帽os desde la fecha de concesi贸n

Esta concesi贸n de compensaci贸n en acciones parece formar parte del programa est谩ndar de compensaci贸n para directores de la empresa. Las opciones se otorgaron con propiedad directa, y la presentaci贸n fue realizada por el apoderado Rodney Young el 24 de junio de 2025. Esta transacci贸n representa una nueva posici贸n para el director, ya que no se reportaron participaciones previas en la presentaci贸n.

RAPT Therapeutics鞚� 鞚挫偓 Scott Braunstein電� 2025雲� 6鞗� 21鞚检棎 欤检嫕 毵れ垬靹犿儩甓岇潉 攵赌鞐皼鞎橃溂氅�, 鞚措姅 鞚� Form 4 鞝滌稖靹滌棎 氤搓碃霅橃棃鞀惦媹雼�. 韺岇儩 歃濌秾 瓯半灅 靹鸽秬靷暛鞚� 雼れ潓瓿� 臧欖姷雼堧嫟:

  • 氤错喌欤茧ゼ 毵れ垬頃� 靾� 鞛堧姅 25,000欤� 欤检嫕毵れ垬靹犿儩甓� 攵赌鞐�
  • 頄夓偓臧�瓴╈潃 欤茧嫻 $7.43搿� 靹れ爼
  • 鞓奠厴 毵岆鞚检潃 2035雲� 6鞗� 21鞚�
  • 氩犾姢韺� 鞚检爼: 攵赌鞐澕搿滊秬韯� 3雲勱皠 毵る厔 霃欖澕頃� 牍勳湪搿� 甓岆Μ 旆摑

鞚� 欤检嫕 氤挫儊 攵赌鞐姅 須岇偓鞚� 響滌 鞚挫偓 氤挫儊 頂勲攴鸽灗鞚� 鞚茧秬搿� 氤挫瀰雼堧嫟. 鞓奠厴鞚� 歆侅爲 靻岇湢 順曧儨搿� 攵赌鞐悩鞐堨溂氅�, 鞝滌稖鞚� 2025雲� 6鞗� 24鞚� 雽�毽澑鞚� Rodney Young鞐� 鞚橅暣 鞚措（鞏挫鞀惦媹雼�. 鞚� 瓯半灅電� 鞚挫偓鞐愱矊 靸堧鞖� 歆�攵勳潉 鞚橂頃橂┌, 鞚挫爠鞐� 氤挫湢 雮挫棴鞚� 氤搓碃霅橃 鞎婌晿鞀惦媹雼�.

Scott Braunstein, directeur de RAPT Therapeutics, a re莽u une attribution d'options d'achat d'actions le 21 juin 2025, comme indiqu茅 dans ce formulaire 4. Les d茅tails de la transaction sur titres d茅riv茅s sont les suivants :

  • Attribution de 25 000 options d'achat d'actions pour acqu茅rir des actions ordinaires
  • Prix d'exercice fix茅 脿 7,43 $ par action
  • Les options expirent le 21 juin 2035
  • Calendrier d'acquisition : versements annuels 茅gaux sur trois ans 脿 partir de la date d'attribution

Cette attribution de r茅mun茅ration en actions semble faire partie du programme standard de r茅mun茅ration des administrateurs de l'entreprise. Les options ont 茅t茅 attribu茅es sous forme de propri茅t茅 directe, et le d茅p么t a 茅t茅 effectu茅 par le mandataire Rodney Young le 24 juin 2025. Cette transaction repr茅sente une nouvelle position pour le directeur, aucun titre ant茅rieur n'ayant 茅t茅 d茅clar茅 dans le d茅p么t.

Scott Braunstein, Direktor von RAPT Therapeutics, erhielt am 21. Juni 2025 eine Zuteilung von Aktienoptionen, wie in diesem Formular 4 gemeldet. Die Details der Derivattransaktion umfassen:

  • Zuteilung von 25.000 Aktienoptionen zum Kauf von Stammaktien
  • Aus眉bungspreis festgelegt auf 7,43 $ pro Aktie
  • Optionen laufen am 21. Juni 2035 ab
  • Vesting-Plan: Gleichm盲脽ige j盲hrliche Raten 眉ber drei Jahre ab dem Zuteilungsdatum

Diese Aktienverg眉tung scheint Teil des standardm盲脽igen Verg眉tungsprogramms f眉r Direktoren des Unternehmens zu sein. Die Optionen wurden in Form von Direktbesitz gew盲hrt, und die Einreichung erfolgte durch den Bevollm盲chtigten Rodney Young am 24. Juni 2025. Diese Transaktion stellt eine neue Position f眉r den Direktor dar, da in der Einreichung keine vorherigen Best盲nde gemeldet wurden.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Braunstein Scott
(Last) (First) (Middle)
C/O RAPT THERAPEUTICS, INC.
561 ECCLES AVENUE
(Street)
SOUTH SAN FRANCISCO CA 94080
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
RAPT Therapeutics, Inc. [ RAPT ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/21/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Director Stock Option (right to buy) $7.43 06/21/2025 A 25,000 (1) 06/21/2035 Common Stock 25,000 $0 25,000 D
Explanation of Responses:
1. The shares subject to the option shall vest in three successive equal annual installments over the three-year period measured from the date of grant of June 21, 2025.
/s/ Rodney Young, Attorney-in-Fact 06/24/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

What stock options did RAPT Therapeutics director Scott Braunstein receive on June 21, 2025?

Scott Braunstein received 25,000 stock options with an exercise price of $7.43 per share. These options were granted on June 21, 2025, and will expire on June 21, 2035.

What is the vesting schedule for RAPT director Braunstein's stock options granted in June 2025?

The stock options will vest in three equal annual installments over a three-year period, starting from the grant date of June 21, 2025.

Who filed the Form 4 for RAPT Therapeutics (RAPT) on June 28, 2025?

The Form 4 was filed for Scott Braunstein, who serves as a Director of RAPT Therapeutics. The form was signed by Rodney Young as Attorney-in-Fact on June 24, 2025.

What is the total value of RAPT stock options granted to Scott Braunstein in June 2025?

Scott Braunstein received 25,000 stock options with an exercise price of $7.43 per share. The options were reported with a price of $0, as they were granted as part of director compensation and not purchased.

Did RAPT director Scott Braunstein make any direct stock purchases or sales in this Form 4 filing?

No, the Form 4 filing shows no direct purchases or sales of RAPT common stock. The only reported transaction was the grant of 25,000 stock options as part of director compensation.
Stock RAPT logo
Rapt Therapeutics, Inc.

NASDAQ:RAPT

RAPT Rankings

#6028 Ranked by Market Cap
N/A Ranked by Dividends

RAPT Latest News

Jun 23, 2025
RAPT Therapeutics Names Two Industry Veterans to its Board of Directors
Jun 13, 2025
RAPT Therapeutics Announces Effective Date for 1-for-8 Reverse Stock Split
Jun 4, 2025
RAPT Therapeutics to Participate in Upcoming Investor Conferences
May 8, 2025
RAPT Therapeutics Reports First Quarter 2025 Financial Results
Apr 15, 2025
RAPT Therapeutics Deepens Expertise in Allergic Diseases with Appointment of聽Jessica Savage, M.D., M.H.S., as Vice President, Clinical Development

RAPT Latest SEC Filings

Jun 30, 2025
[Form 4] RAPT Therapeutics, Inc. Insider Trading Activity
Jun 30, 2025
[Form 3] RAPT Therapeutics, Inc. Initial Statement of Beneficial Ownership
Jun 24, 2025
[Form 3] RAPT Therapeutics, Inc. Initial Statement of Beneficial Ownership
Jun 24, 2025
[Form 4] RAPT Therapeutics, Inc. Insider Trading Activity
Jun 24, 2025
[Form 4] RAPT Therapeutics, Inc. Insider Trading Activity

RAPT Stock Data

135.93M
12.71M
0.49%
96.43%
1.99%
Biotechnology
Pharmaceutical Preparations
United States
SOUTH SAN FRANCISCO